Florida Center for Allergy and Asthma Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$991,168	79
2024	Research	$503,653	95
2023	Research	$429,912	65
2022	Research	$168,998	33
2021	Research	$182,711	16
2020	Research	$590,195	40
2019	Research	$890,803	57

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $1,339,458 29 payments
GlaxoSmithKline, LLC. $1,167,004 257 payments
Teva Pharmaceuticals USA, Inc. $716,616 53 payments
Amphastar Pharmaceuticals, Inc. $436,265 2 payments
Genzyme Corporation $85,063 26 payments
Genentech, Inc. $11,802 5 payments
Incyte Corporation $1,233 13 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $693,313 46 payments
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Dose Find $302,999 35 payments
Phamacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients $269,112 1 payment
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $260,217 2 payments
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co $216,649 2 payments
A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $187,140 60 payments
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks $186,325 4 payments
Pharmacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients $167,153 1 payment
A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou $161,754 40 payments
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines $157,120 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.